{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T22:33:09Z","timestamp":1720564389782},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.mehy.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T15:29:50Z","timestamp":1531841390000},"page":"6-10","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Melatonin: A hypothesis for Kawasaki disease treatment"],"prefix":"10.1016","volume":"119","author":[{"given":"Eva","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Pati\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel J.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Gil-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mehy.2018.07.010_b0005","first-page":"178","article-title":"Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children","volume":"16","author":"Kawasaki","year":"1967","journal-title":"Arerugi"},{"issue":"9433","key":"10.1016\/j.mehy.2018.07.010_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(04)16814-1","article-title":"Kawasaki syndrome","volume":"364","author":"Burns","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2018.07.010_b0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cupe.2004.09.002","article-title":"Complications of Kawasaki disease","volume":"15","author":"Tizard","year":"2005","journal-title":"Curr Pediatrics"},{"issue":"12","key":"10.1016\/j.mehy.2018.07.010_b0020","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00431-003-1329-1","article-title":"Rhabdomyolysis in a patient with Kawasaki disease","volume":"162","author":"Watanabe","year":"2003","journal-title":"Eur J Pediatr."},{"key":"10.1016\/j.mehy.2018.07.010_b0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1155\/2013\/831834","article-title":"Kidney and urinary tract involvement in kawasaki disease","volume":"2013","author":"Watanabe","year":"2013","journal-title":"Int J Pediatr"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s00467-006-0086-6","article-title":"Hyponatremia in Kawasaki disease","volume":"21","author":"Watanabe","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1016\/j.mehy.2018.07.010_b0035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2015.04.002","article-title":"Kawasaki disease: an evolving paradigm","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12872-018-0765-9","article-title":"The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease","volume":"18","author":"Ishikawa","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0045","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/infdis\/158.6.1296","article-title":"A nationwide incidence survey of Kawasaki disease in 1985\u20131986 in Japan","volume":"158","author":"Yanagawa","year":"1988","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.mehy.2018.07.010_b0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3345\/kjp.2015.58.3.84","article-title":"Update of genetic susceptibility in patients with Kawasaki disease","volume":"58","author":"Yoon","year":"2015","journal-title":"Korean J Pediatr"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/s10165-011-0468-x","article-title":"Serum adipokine profiles in Kawasaki disease","volume":"22","author":"Kemmotsu","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2012.01.013","article-title":"Relationship between adipokines and coronary artery aneurysm in children with Kawasaki disease","volume":"160","author":"Liu","year":"2012","journal-title":"Transl Res"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038998","article-title":"Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study","volume":"7","author":"Orenstein","year":"2012","journal-title":"PLoS One"},{"issue":"5 Pt 2","key":"10.1016\/j.mehy.2018.07.010_b0070","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0002-8703(99)70266-8","article-title":"Atherosclerosis is an inflammatory disease","volume":"138","author":"Ross","year":"1999","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00246-015-1280-8","article-title":"Elevated inducible nitric oxide levels and decreased hydrogen sulfide levels can predict the risk of coronary artery ectasia in Kawasaki disease","volume":"37","author":"Song","year":"2016","journal-title":"Pediatr Cardiol"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11926-014-0423-x","article-title":"Kawasaki disease: pathophysiology, clinical manifestations, and management","volume":"16","author":"Dimitriades","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2249.2010.04236.x","article-title":"The T helper type 17\/regulatory T cell imbalance in patients with acute Kawasaki disease","volume":"162","author":"Jia","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.mehy.2018.07.010_b0090","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.4049\/jimmunol.0802484","article-title":"IL-10 is a negative regulatory factor of CAWS-vasculitis in CBA\/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA\/N mice","volume":"183","author":"Miura","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1348-0421.2005.tb03708.x","article-title":"Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans -derived substances","volume":"49","author":"Oharaseki","year":"2005","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.mehy.2018.07.010_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2017.01.027","article-title":"Redox regulation of cardiovascular inflammation \u2013 Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species","volume":"109","author":"Wenzel","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10.1016\/j.mehy.2018.07.010_b0105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1089\/ars.2012.4660","article-title":"Does oxidative stress play a critical role in cardiovascular complications of Kawasaki disease?","volume":"17","author":"Straface","year":"2012","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"10.1016\/j.mehy.2018.07.010_b0110","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s10753-011-9398-1","article-title":"Regulation of oxidative stress in patients with Kawasaki disease","volume":"35","author":"Sekine","year":"2012","journal-title":"Inflammation"},{"issue":"10","key":"10.1016\/j.mehy.2018.07.010_b0115","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1253\/circj.CJ-10-0605","article-title":"Dynamics of reactive oxygen metabolites and biological antioxidant potential in the acute stage of Kawasaki disease","volume":"75","author":"Yahata","year":"2011","journal-title":"Circ J"},{"issue":"7","key":"10.1016\/j.mehy.2018.07.010_b0120","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1253\/circj.CJ-07-0635","article-title":"IVIG reduced vascular oxidative stress in patients with Kawasaki disease","volume":"73","author":"Takatsuki","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.mehy.2018.07.010_b0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2014.11.223","article-title":"Red blood cells as bioindicators of cardiovascular risk in Kawasaki disease: a case report","volume":"181","author":"Pietraforte","year":"2015","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.mehy.2018.07.010_b0130","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrmicro1853","article-title":"Searching for the cause of Kawasaki disease-cytoplasmic inclusion bodies provide new insight","volume":"6","author":"Rowley","year":"2008","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"10.1016\/j.mehy.2018.07.010_b0135","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00431-017-2937-5","article-title":"Dissecting Kawasaki disease: a state-of-the-art review","volume":"176","author":"Dietz","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2188\/jea.JE20110131","article-title":"Epidemiology of Kawasaki disease in Asia, Europe, and the United States","volume":"22","author":"Uehara","year":"2012","journal-title":"J Epidemiol"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ng.2007.59","article-title":"ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms","volume":"40","author":"Onouchi","year":"2008","journal-title":"Nat Genet."},{"key":"10.1016\/j.mehy.2018.07.010_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ceca.2018.01.002","article-title":"A critical appraisal of the role of intracellular Ca(2+)-signaling pathways in Kawasaki disease","volume":"71","author":"Bijnens","year":"2018","journal-title":"Cell Calcium"},{"issue":"14","key":"10.1016\/j.mehy.2018.07.010_b0155","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/hmg\/ddq176","article-title":"Common variants in CASP3 confer susceptibility to Kawasaki disease","volume":"19","author":"Onouchi","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.mehy.2018.07.010_b0160","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2008.07.025","article-title":"TGF-beta: a master of all T cell trades","volume":"134","author":"Li","year":"2008","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ni1549","article-title":"Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer","volume":"9","author":"Tone","year":"2008","journal-title":"Nat Immunol."},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3349\/ymj.2016.57.1.15","article-title":"Recent advances in Kawasaki disease","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0175","first-page":"1708","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young","volume":"114","author":"Newburger","year":"2004","journal-title":"Am. Heart Assoc. Pediatrics"},{"issue":"23","key":"10.1016\/j.mehy.2018.07.010_b0180","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mehy.2018.07.010_b0185","first-page":"163","article-title":"overview of pharmacological treatment options for pediatric patients with refractory Kawasaki disease","volume":"20","author":"Saneeymehri","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.mehy.2018.07.010_b0190","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00431-007-0642-5","article-title":"Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin","volume":"167","author":"Miura","year":"2008","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.mehy.2018.07.010_b0195","first-page":"651","article-title":"Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease","volume":"113","author":"Maury","year":"1989","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0200","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"153","author":"Burns","year":"2008","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0205","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jpeds.2010.06.014","article-title":"Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease","volume":"157","author":"Choueiter","year":"2010","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cyto.2014.07.003","article-title":"Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange","volume":"70","author":"Fujimaru","year":"2014","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.mehy.2018.07.010_b0215","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1542\/peds.112.4.986","article-title":"Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect","volume":"112","author":"Kuijpers","year":"2003","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.mehy.2018.07.010_b0220","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/INF.0b013e318220c3cf","article-title":"Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin","volume":"30","author":"Suzuki","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pedneo.2011.11.003","article-title":"Kawasaki disease: an update on diagnosis and treatment","volume":"53","author":"Kuo","year":"2012","journal-title":"Pediatr Neonatol"},{"issue":"4","key":"10.1016\/j.mehy.2018.07.010_b0230","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3349\/ymj.2002.43.4.527","article-title":"A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate","volume":"43","author":"Lee","year":"2002","journal-title":"Yonsei Med J"},{"issue":"6","key":"10.1016\/j.mehy.2018.07.010_b0235","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1542\/peds.105.6.e78","article-title":"Initial intravenous gammaglobulin treatment failure in Kawasaki disease","volume":"105","author":"Wallace","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.mehy.2018.07.010_b0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fphar.2017.00163","article-title":"IL-1 inhibition may have an important role in treating refractory Kawasaki disease","volume":"8","author":"Dusser","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2042018813476084","article-title":"Therapeutic applications of melatonin","volume":"4","author":"Kostoglou-Athanassiou","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.mehy.2018.07.010_b0250","first-page":"39","article-title":"Capozide-50 alone and in combination with melatonin in therapy of hypertension","volume":"78","author":"Zaslavskaia","year":"2000","journal-title":"Klin Med (Mosk)"},{"key":"10.1016\/j.mehy.2018.07.010_b0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lfs.2016.11.031","article-title":"Melatonin's role as a co-adjuvant treatment in colonic diseases: a review","volume":"170","author":"Esteban-Zubero","year":"2017","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.mehy.2018.07.010_b0260","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.yebeh.2004.01.012","article-title":"Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial","volume":"5","author":"Gupta","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.mehy.2018.07.010_b0265","article-title":"Anti-inflammatory effects of melatonin: a mechanistic review","volume":"1\u201362","author":"Nabavi","year":"2018","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0270","first-page":"41","article-title":"Epigenetic regulation: a new research area for melatonin?","volume":"44","author":"Korkmaz","year":"2008","journal-title":"J Pineal Res"},{"issue":"3\u20134","key":"10.1016\/j.mehy.2018.07.010_b0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000014635","article-title":"Significance of melatonin in antioxidative defense system: reactions and products","volume":"9","author":"Tan","year":"2000","journal-title":"Biol Signals Recept"},{"key":"10.1016\/j.mehy.2018.07.010_b0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/molecules23020509","article-title":"Mitochondria: central organelles for melatoni\u0144s antioxidant and anti-aging actions","volume":"23","author":"Reiter","year":"2018","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1385\/ENDO:27:2:119","article-title":"Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance","volume":"27","author":"Hardeland","year":"2005","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-079X.2011.00916.x","article-title":"Melatonin as a natural ally against oxidative stress: a physicochemical examination","volume":"51","author":"Galano","year":"2011","journal-title":"J Pineal Res"},{"issue":"4","key":"10.1016\/j.mehy.2018.07.010_b0295","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jpi.12267","article-title":"Melatonin: an ancient molecule that makes oxygen metabolically tolerable","volume":"59","author":"Manchester","year":"2015","journal-title":"J Pineal Res"},{"issue":"1","key":"10.1016\/j.mehy.2018.07.010_b0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jpi.12045","article-title":"Melatonin mediates protective effects on inflammatory response induced by interleukin-1 beta in human mesenchymal stem cells","volume":"55","author":"Liu","year":"2013","journal-title":"J Pineal Res"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjp.0707225","article-title":"Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro","volume":"151","author":"Silva","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2018.07.010_b0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-079X.2010.00761.x","article-title":"Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines","volume":"48","author":"Tocharus","year":"2010","journal-title":"J Pineal Res"},{"key":"10.1016\/j.mehy.2018.07.010_b0315","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-018-0508-7","article-title":"The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials","author":"Akbari","year":"2018","journal-title":"Inflammopharmacology"},{"issue":"4","key":"10.1016\/j.mehy.2018.07.010_b0320","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms14048638","article-title":"Melatonin: buffering the immune system","volume":"14","author":"Carrillo-Vico","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.mehy.2018.07.010_b0325","first-page":"423","article-title":"The modulatory role of melatonin on immune responsiveness","volume":"7","author":"Carrillo-Vico","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.mehy.2018.07.010_b0330","first-page":"63(4)","article-title":"Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients","author":"Alvarez-Sanchez","year":"2017","journal-title":"J Pineal Res"},{"issue":"33","key":"10.1016\/j.mehy.2018.07.010_b0335","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.2174\/0929867322666150827093730","article-title":"Potential relevance of melatonin against some infectious agents: a review and assessment of recent research","volume":"22","author":"Elmahallawy","year":"2015","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.mehy.2018.07.010_b0340","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-079X.2007.00516.x","article-title":"Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule","volume":"44","author":"Tekbas","year":"2008","journal-title":"J Pineal Res"},{"key":"10.1016\/j.mehy.2018.07.010_b0345","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.biopha.2017.11.007","article-title":"The potential use of melatonin to treat protozoan parasitic infections: A review","volume":"97","author":"Daryani","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.mehy.2018.07.010_b0350","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.4049\/jimmunol.1600388","article-title":"Inositol-triphosphate 3-kinase c mediates inflammasome activation and treatment response in Kawasaki disease","volume":"197","author":"Alphonse","year":"2016","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.mehy.2018.07.010_b0355","doi-asserted-by":"crossref","first-page":"18221","DOI":"10.3390\/ijms151018221","article-title":"Melatonin, noncoding RNAs, messenger RNA stability and epigenetics-evidence, hints, gaps and perspectives","volume":"15","author":"Hardeland","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mehy.2018.07.010_b0360","first-page":"1835195","article-title":"Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int","author":"Favero","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.mehy.2018.07.010_b0365","first-page":"119","article-title":"Vascular endothelial cells and dysfunctions: role of melatonin","volume":"5","author":"Rodella","year":"2013","journal-title":"Front Biosci (Elite Ed)"},{"key":"10.1016\/j.mehy.2018.07.010_b0370","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12471","article-title":"Protective role of melatonin in cardiac ischemia-reperfusion injury: From pathogenesis to targeted therapy","volume":"64","author":"Zhou","year":"2018","journal-title":"J Pineal Res"},{"issue":"18","key":"10.1016\/j.mehy.2018.07.010_b0375","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1053\/euhj.1999.1527","article-title":"Decreased melatonin synthesis in patients with coronary artery disease","volume":"20","author":"Sakotnik","year":"1999","journal-title":"Eur Heart J"},{"issue":"8984","key":"10.1016\/j.mehy.2018.07.010_b0380","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0140-6736(95)92935-5","article-title":"Melatonin for treatment of chronic refractory sarcoidosis","volume":"346","author":"Cagnoni","year":"1995","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mehy.2018.07.010_b0385","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00007890-199904150-00022","article-title":"Melatonin: an antioxidant protects against cyclosporine-induced nephrotoxicity","volume":"67","author":"Kumar","year":"1999","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.mehy.2018.07.010_b0390","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0041-1345(00)01535-9","article-title":"The beneficial effect of melatonin for cyclosporine hepatotoxicity in rats","volume":"32","author":"Kwak","year":"2000","journal-title":"Transplant Proc"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718306790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718306790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T17:08:25Z","timestamp":1536599305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987718306790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":78,"alternative-id":["S0306987718306790"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2018.07.010","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melatonin: A hypothesis for Kawasaki disease treatment","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}